Luye Pharma Group, a member of Luye Life Sciences Group, is an international pharmaceutical company with a focus on targeting Central Nervous System (CNS), Oncology and other therapeutic areas.Global R&D, global manufacturing, and the global sale of innovative medications are the company’s three main strategic priorities.Key products covering the central nervous system, oncology and other therapeutic areas with 30+ products covering 80+ countries and regions worldwide including large pharmaceutical markets - China, U.S., Europe, Japan, APAC as well as fastgrowing emerging markets.R&D Centers in China, U.S. and Europe with a robust pipeline of 30+ drug candidates in China and 10+ drug candidates overseas A series of biosimilars and innovative biopharmaceuticals are under development.Several new drugs and new formulations in CNS and Oncology therapeutic areas are under clinical trials in the U.S., Europe and Japan.
Luye Pharma Group, a member of Luye Life Sciences Group, is an international pharmaceutical company with a focus on targeting Central Nervous System (CNS), Oncology and other therapeutic areas.Global R&D, global manufacturing, and the global sale of innovative medications are the company’s three main strategic priorities.Key products covering the central nervous system, oncology and other therapeutic areas with 30+ products covering 80+ countries and regions worldwide including large pharmaceutical markets - China, U.S., Europe, Japan, APAC as well as fastgrowing emerging markets.R&D Centers in China, U.S. and Europe with a robust pipeline of 30+ drug candidates in China and 10+ drug candidates overseas A series of biosimilars and innovative biopharmaceuticals are under development.Several new drugs and new formulations in CNS and Oncology therapeutic areas are under clinical trials in the U.S., Europe and Japan.
Luye Pharma Group, a member of Luye Life Sciences Group, is an international pharmaceutical company with a focus on targeting Central Nervous System (CNS), Oncology and other therapeutic areas.Global R&D, global manufacturing, and the global sale of innovative medications are the company’s three main strategic priorities.Key products covering the central nervous system, oncology and other therapeutic areas with 30+ products covering 80+ countries and regions worldwide including large pharmaceutical markets - China, U.S., Europe, Japan, APAC as well as fastgrowing emerging markets.R&D Centers in China, U.S. and Europe with a robust pipeline of 30+ drug candidates in China and 10+ drug candidates overseas A series of biosimilars and innovative biopharmaceuticals are under development.Several new drugs and new formulations in CNS and Oncology therapeutic areas are under clinical trials in the U.S., Europe and Japan.